FDA approves Glaxo, Theravance’s Breo Ellipta asthma drug – Reuters


Reuters

FDA approves Glaxo, Theravance's Breo Ellipta asthma drug
Reuters
(Reuters) – The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said. The FDA declined to approve Breo for younger …
Glaxo Wins U.S. Approval to Sell Breo Only to Adults With AsthmaBloomberg
FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the USMarketWatch
FDA Okays Breo Ellipta for Asthma in AdultsMedscape
StreetInsider.com –CNNMoney –HCPLive
all 23 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.